Biophytis
Metabolic and age-related diseases.
Launch date
Employees
Market cap
€2.6m
Enterprise valuation
€3m (Public information from Sep 2024)
Share price
$7.03 BPTS
Company register number 492002225
Paris Île-de-France (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | 4.6m | 4.8m | 18.7m |
| % growth | - | - | - | - | - | 4 % | 290 % |
| EBITDA | (14.2m) | (26.8m) | (23.7m) | (13.8m) | (14.8m) | (13.9m) | (5.4m) |
| % EBITDA margin | - | - | - | - | (322 %) | (290 %) | (29 %) |
| Profit | (17.1m) | (31.2m) | (24.2m) | (17.0m) | (19.8m) | (16.9m) | (8.4m) |
| % profit margin | - | - | - | - | (430 %) | (352 %) | (45 %) |
| EV / revenue | - | - | - | - | 0.6x | 0.6x | 0.1x |
| EV / EBITDA | -6.5x | -2.3x | -0.3x | -0.3x | -0.2x | -0.2x | -0.5x |
| R&D budget | 9.9m | 19.7m | 16.0m | 8.8m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | Support Program | |
$2.6m | Series B | ||
| N/A | €10.0m Valuation: €32.7m | IPO | |
* | N/A | $12.0m | Post IPO Equity |
€600k | Post IPO Debt | ||
€380k | Grant | ||
€10.0m | Post IPO Debt | ||
* | N/A | €2.3m | Post IPO Equity |
| Total Funding | €2.7m | ||
Recent News about Biophytis
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.